Prime Medicine, Inc.
SEC CIK 1894562 · PRME · last insider filing 2026-06-08
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Nelsen Robert | Director | filed 2022 - 2026 |
| Foster-Cheek Kaye I | Director | filed 2022 - 2026 |
| Schenkein David P | Director | filed 2022 - 2026 |
| Marrazzo Jeffrey D | Director | filed 2023 - 2026 |
| Kelly Michael Aaron | Director | filed 2022 - 2026 |
| Chung Wendy | Director | filed 2022 - 2026 |
| Cahill Thomas | Director | filed 2022 - 2026 |
| Reine Allan | Director · Chief Financial Officer | filed 2024 - 2026 |
| Gottesdiener Keith Michael | Director · See Remarks | filed 2022 - 2025 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Makhni Svetlana Ni | Chief Financial Officer | filed 2026 - 2026 |
| Alenson Carman | See Remarks | filed 2022 - 2026 |
| LEE ANN L. | Chief Technical Officer | filed 2022 - 2026 |
| Brudnick Richard | Chief Business Officer | filed 2022 - 2025 |
| Duffield Jeremy | Chief Scientific Officer | filed 2022 - 2025 |
| Goldwasser Meredith | SVP, Strategy & Corporate Ops. | filed 2022 - 2025 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.